| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18317 R77148 |
Chan (Controls unexposed, sick), 2024 | Nervous system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Monotherapy: SSRI only Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 0.92 [0.06;15.07] C | 0/66 36/4,413 | 36 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18315 R77124 |
Chan - SNRI (Controls exposed to TCA), 2024 | Nervous system malformations | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.59 [0.03;11.64] C excluded (control group) |
0/77 3/322 | 3 | 77 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18316 R77136 |
Chan - SNRI (Controls unexposed, general pop), 2024 | Nervous system malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: No Monotherapy: SNRI only |
1.58 [0.10;25.57] C excluded (control group) |
0/77 1,899/462,377 | 1,899 | 77 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15171 R62279 |
Benevent - SNRI, 2023 | Nervous system anomalies | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: SNRI only | 1.79 [0.25;12.83] C | 1/314 261/146,855 | 262 | 314 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11684 R42948 |
Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 | Nervous system malformations | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
1.00 [0.28;3.54] excluded (control group) |
-/1,438 12/5,751 | - | 1,438 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11685 R42964 |
Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 | Nervous system malformations | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.50 [0.25;8.98] | -/1,434 -/1,435 | - | 1,434 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11745 R43129 |
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 | Central Nervous System malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.81 [0.30;2.16] excluded (control group) |
-/2,532 -/- | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11746 R43143 |
Huybrechts - Duloxetine (Controls unexposed, sick), 2020 | Central Nervous System malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.67 [0.18;2.42] | -/2,532 -/2,456 | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11696 R43024 |
Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 | Nervous system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.19 [0.55;2.58] | -/738 -/14,847 | - | 738 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.11 [0.62;1.99] | 298 | 5,084 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick; 4: Controls unexposed, sick;
Asymetry test p-value = 0.9140 (by Egger's regression)
slope=0.0660 (0.3962); intercept=0.0702 (0.5979); t=0.1173; p=0.9140
excluded 11745, 11684, 18315, 18316